Serum IL-10 predicts worse outcome in cancer patients: A meta-analysis

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Zhao, Shuai ^a,b   Wu, Dang ^a,b   Wu, Pin ^a,b   Wang, Zhen ^a,b   Huang, Jian ^a,b   Gao, Jian Xin ^c  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; TUMOR MARKER; IL10 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CHILD; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE FREE SURVIVAL; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MANTEL HAENSZEL TEST; META ANALYSIS (TOPIC); OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SOLID TUMOR; SURVIVAL TIME; VERY ELDERLY; BLOOD; META ANALYSIS; MORTALITY; NEOPLASM; PROGNOSIS; SURVIVAL RATE;

BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; HUMANS; INTERLEUKIN-10; NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 84947721328     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0139598     Document Type: Article

References (58)

1. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer cell. 2005; 7(3):211-7. doi:10.1016/j.ccr.2005.02.013 PMID: 15766659.
2. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001; 357(9255):539-45. doi:10.1016/S0140-6736(00)04046-0 PMID: 11229684.
3. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420(6917):860-7. doi:10.1038/nature01322 PMID: 12490959; PubMed Central PMCID: PMC2803035.
4. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006; 441 (7092):431-6. doi:10.1038/nature04870 PMID: 16724054.
5. Mantovani A, Allavena P, Sica A., Balkwill F. Cancer-related inflammation. Nature. 2008; 454 (7203):436-44. doi:10.1038/nature07205 PMID: 18650914.
6. Baniyash M. Chronic inflammation, immunosuppression and cancer: new insights and outlook. Seminars in cancer biology. 2006; 16(1):80-8. doi:10.1016/j.semcancer.2005.12.002 PMID: 16420981.
7. Smyth MJ, Cretney E, Kershaw M.H., Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunological reviews. 2004; 202:275-93. doi:10.1111/j.0105-2896.2004.00199.x PMID: 15546400.
8. Hanada T, Yoshimura A. Regulation of cytokine signaling and inflammation. Cytokine & growth factor reviews. 2002; 13(4-5):413-21. PMID: 12220554.
9. Chambers SK. Role of CSF-1 in progression of epithelial ovarian cancer. Future oncology. 2009; 5 (9):1429-40. doi:10.2217/fon.09.103 PMID: 19903070; PubMed Central PMCID: PMC2830097.
10. Locksley RM, Killeen N, Lenardo MJ The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001; 104(4):487-501. PMID: 11239407.
11. Apte RN, Voronov E. Interleukin-1 - a major pleiotropic cytokine in tumor-host interactions. Seminars in cancer biology. 2002; 12(4):277-90. PMID: 12147202.
12. Villa-Morales M., Fernandez-Piqueras J. Targeting the Fas/FasL signaling pathway in cancer therapy. Expert opinion on therapeutic targets. 2012; 16(1):85-101. doi:10.1517/14728222.2011.628937 PMID: 22239437.
13. Waldner MJ, Neurath MF Targeting the VEGF signaling pathway in cancertherapy. Expert opinion on therapeutic targets. 2012; 16(1):5-13. doi:10.1517/14728222.2011.641951 PMID: 22239434.
14. Principe DR, Doll JA, Bauer J, Jung B., Munshi HG, Bartholin L, et al. TGF-beta: duality of function between tumor prevention and carcinogenesis. Journal of the National Cancer Institute. 2014; 106(2): djt369. doi:10.1093/jnci/djt369 PMID: 24511106; PubMed Central PMCID: PMC3952197.
15. Maynard CL, Harrington LE, Janowski K.M., Oliver JR, Zindl CL, Rudensky AY, et al RegulatoryTcells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. Nature immunology. 2007; 8(9):931-41. doi:10.1038/ni1504 PMID: 17694059.
16. Del Prete G., De Carli M, Almerigogna F, Giudizi M.G., Biagiotti R., Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2)T cell clones and inhibits their antigen-specific proliferation and cytokine production. Journal of immunology (Baltimore, Md: 1950). 1993; 150 (2):353-60. PMID: 8419468.
17. Fiorentino DF, Bond MW, Mosmann TR Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production byTh1 clones. The Journal of experimental medicine. 1989; 170 (6):2081-95. PMID: 2531194; PubMed Central PMCID: PMC2189521.
18. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annual review of immunology. 1993; 11:165-90. doi:10.1146/annurev.iy.11.040193.001121 PMID: 8386517.
19. Mocellin S, Panelli MC, Wang E, Nagorsen D., Marincola FM. The dual role of IL-10. Trends in immunology. 2003; 24(1):36-43. Epub 2002/12/24. PMID: 12495723.
20. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annual review of immunology. 2001; 19:683-765. doi:10.1146/annurev.immunol.19.1.683 PMID: 11244051.
21. Dennis KL, Blatner NR, Gounari F, Khazaie K. Current status of interleukin-10 and regulatory T-cells in cancer. Current opinion in oncology. 2013; 25(6):637-45. Epub 2013/10/01. doi:10.1097/cco.0000000000000006 PMID: 24076584.
22. Hamidullah, Changkija B, Konwar R. Role of interleukin-10 in breast cancer. Breast cancer research and treatment. 2012; 133(1):11-21. Epub 2011/11/08. doi:10.1007/s10549-011-1855-x PMID: 22057973.
23. Sato T, Terai M, Tamura Y., Alexeev V, Mastrangelo MJ, Selvan SR Interleukin 10 in the tumor micro-environment: a target for anticancer immunotherapy. Immunologic research. 2011; 51(2-3):170-82. Epub 2011/12/06. doi:10.1007/s12026-011-8262-6 PMID: 22139852.
24. Vicari AP, Trinchieri G. Interleukin-10 in viral diseases and cancer: exiting the labyrinth? Immunological reviews. 2004; 202:223-36. Epub 2004/11/18. doi:10.1111/j.0105-2896.2004.00216.x PMID: 15546396.
25. Kundu N, Beaty TL, Jackson M.J., Fulton AM. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. Journal of the National Cancer Institute. 1996; 88(8):536-41. PMID: 8606382.
26. Sarris AH, Kliche KO, Pethambaram P, Preti A., Tucker S, Jackow C, et al Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 1999; 10(4):433-40. Epub 1999/06/17. PMID: 10370786.
27. Axdorph U, Sjoberg J, Grimfors G., Landgren O, Porwit-MacDonald A, Bjorkholm M. Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2000; 11 (11):1405-11. Epub 2001/01/06. PMID: 11142480.
28. Salgami EV, Efstathiou SP, Vlachakis V, Sekara E.V., Syrigos KN, Roussou PP. High pretreatment interleukin-10 is an independent predictor of poor failure-free survival in patients with Hodgkin's lymphoma. Haematologia. 2002; 32(4):377-87. Epub 2003/06/14. PMID: 12803112.
29. Visco C, Vassilakopoulos TP, Kliche KO, Nadali G, Viviani S., Bonfante V, et al. Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy. Leukemia & lymphoma. 2004; 45(10):2085-92. Epub 2004/09/17. doi:10.1080/10428190410001712234 PMID: 15370254.
30. Kaio E, Tanaka S, Oka S., Hiyama T, Kitadai Y, Haruma K., et al. Clinical significance of thrombospon-din-1 expression in relation to vascular endothelial growth factor and interleukin-10 expression at the deepest invasive tumor site of advanced colorectal carcinoma. International journal of oncology. 2003; 23(4):901-11. PMID: MEDLINE:12963968.
31. Soria J-C, Moon C, Kemp B.L., Liu DD, Feng L, Tang X, et al Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2003; 9(5):1785-91. PMID: MEDLINE:12738735.
32. Toiyama Y, Miki C, Inoue Y., Minobe S, Urano H, Kusunoki M. Loss of tissue expression of interleukin-10 promotes the disease progression of colorectal carcinoma. Surgery today. 2010; 40(1):46-53. doi:10.1007/s00595-009-4016-7 PMID: MEDLINE:20037839.
33. Terai M, Tamura Y, Alexeev V., Ohtsuka E, Berd D, Mastrangelo M.J., et al. Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential. Cancer immunology, immunotherapy: CII. 2009; 58(8):1307-17. doi:10.1007/s00262-008-0644-9 PMID: 19142637.
34. Chernoff AE, Granowitz EV, Shapiro L, Vannier E., Lonnemann G, Angel JB, et al A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. Journal of immunology (Baltimore, Md: 1950). 1995; 154(10):5492-9. PMID: 7730651.
35. Vicari AP, Chiodoni C, Vaure C., Ait-Yahia S, Dercamp C, Matsos F., et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. The Journal of experimental medicine. 2002; 196(4):541-9. PMID: 12186845; PubMed Central PMCID: PMC2196048.
36. Mumm JB, Oft M. Pegylated IL-10 induces cancer immunity: the surprising role of IL-10 as a potent inducer of IFN-gamma-mediated CD8(+) T cell cytotoxicity. BioEssays: news and reviews in molecular, cellular and developmental biology. 2013; 35(7):623-31. Epub 2013/05/15. doi:10.1002/bies. 201300004 PMID: 23666891.
37. Deeks JJH. AD J. Analysing and presenting results. In: Higgins JPT, Green S, ed Cochrane Handbook for Systematic Reviews of Interventions 425 Chichester, UK: John Wiley & Sons ncer Res. 2006; 15: p. 6341-7.
38. Blay JY, Burdin N, Rousset F., Lenoir G, Biron P, Philip T., et al. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood. 1993; 82(7):2169-74. Epub 1993/10/01. PMID: 8400266.
39. Bohlen H, Kessler M, Sextro M., Diehl V, Tesch H. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Annals of hematology. 2000; 79(3):110-3. Epub 2000/05/10. PMID: 10803931.
40. Chan SL, Mo FKF, Wong CSC, Chan CML, Leung LKS, Hui EP, et al A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. Cancer. 2012; 118(16):3984-92. doi:10.1002/cncr.26726 PMID: MEDLINE:22180222.
41. Cortes JE, Talpaz M, Cabanillas F., Seymour JF, Kurzrock R. Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood. 1995; 85(9):2516-20. PMID: MEDLINE:7537119.
42. De Vita F., Orditura M, Galizia G., Romano C, Infusino S, Auriemma A., et al. Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. Cancer. 1999; 86(10):1936-43. doi: 10.1002/(sici)1097-0142(19991115)86:10<1936::aid-cncr9>3.0.co;2-9 PMID: MEDLINE: 10570416.
43. De Vita F., Orditura M, Galizia G., Romano C, Roscigno A, Lieto E., et al. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest. 2000; 117(2):365-73. doi:10.1378/chest.117.2.365 PMID: MEDLINE:10669676.
44. Ebrahimi B, Tucker SL, Li D, Abbruzzese J.L., Kurzrock R. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer. 2004; 101(12):2727-36. doi:10.1002/cncr. 20672 PMID: MEDLINE:15526319.
45. Evans C, Morrison I, Heriot AG, Bartlett J.B., Finlayson C., Dalgleish AG, et al. The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survival. British journal of cancer. 2006; 94(10):1412-9. doi:10.1038/sj.bjc.6603104 PMID: 20927906.
46. Fayad L, Keating MJ, Reuben J.M., O'Brien S, Lee BN, Lerner S, et al Interleukin-6and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001; 97(1):256-63. doi:10.1182/blood.V97.1.256 PMID: MEDLINE:11133769.
47. Green VL, Irune E, Prasai A., Alhamarneh O, Greenman J, Stafford ND Serum IL10, IL12 and circulating CD4+CD25high T regulatory cells in relation to long-term clinical outcome in head and neck squamous cell carcinoma patients. International journal of oncology. 2012; 40(3):833-9. doi:10.3892/ijo.2011.1259 PMID: MEDLINE:22075762.
48. Hattori E, Okumoto K, Adachi T, Takeda T., Ito J-i, Sugahara K, et al Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma. Hepatology Research. 2003; 27(4):309.
49. Lech-Maranda E., Bienvenu J, Broussais-Guillaumot F, Warzocha K., Michallet A-S, Robak T, et al Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index. Archivum immunologiaeettherapiaeexperimentalis. 2010; 58(2):131-41. doi:10.1007/s00005-010-0066-1 PMID: MEDLINE:20191326.
50. Lech-Maranda E., Grzybowska-Izydorczyk O, Wyka K., Mlynarski W, Borowiec M, Antosik K., et al. Serum tumor necrosis factor-alpha and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status. Archivum immunologiae ettherapiae experimentalis. 2012; 60(6):477-86. doi:10.1007/s00005-012-0197-7 PMID: MEDLINE:22945689.
51. Nacinovic-Duletic A., Stifter S, Dvornik S., Skunca Z, Jonjic N. Correlation of serum IL-6, IL-8and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma. International journal of laboratory hematology. 2008; 30(3):230-9. doi:10.1111/j.1751-553X.2007. 00951.x PMID: MEDLINE:18479302.
52. Nemunaitis J, Fong T, Shabe P., Martineau D, Ando D. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer investigation. 2001; 19 (3):239-47. doi:10.1081/cnv-100102550 PMID: MEDLINE:11338880.
53. Szaflarska A, Szczepanik A, Siedlar M, Czupryna A., Sierzega M, Popiela T, et al Preoperative plasma level of IL-10 but not of proinflammatory cytokines is an independent prognostic factor in patients with gastric cancer. Anticancer research. 2009; 29(12):5005-12. PMID: MEDLINE:20044609.
54. Vassilakopoulos TP, Nadali G, Angelopoulou M.K., Siakantaris MP, Dimopoulou MN, Kontopidou FN, et al Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Haematologica. 2001; 86(3):274-81. PMID: MEDLINE:11255274.
55. Viviani S, Notti P, Bonfante V., Verderio P, Valagussa P, Bonadonna G. Elevated pretreatment serum levels of Il-10 are associated with a poor prognosis in Hodgkin's disease, the milan cancer institute experience. Medical oncology (Northwood, London, England). 2000; 17(1):59-63. doi:10.1007/bf02826218 PMID: MEDLINE:10713662.
56. Chau GY, Wu CW, Lui W.Y., Chang TJ, Kao HL, Wu LH, et al Serum interleukin-10butnotinterleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Annals of surgery. 2000; 231(4):552-8. Epub 2000/04/05. PMID: 10749617; PubMed Central PMCID: PMCPmc1421032.
57. Galizia G, Orditura M, Romano C, Lieto E., Castellano P, Pelosio L, et al Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clinical immunology (Orlando, Fla). 2002; 102(2):169-78. doi:10.1006/clim.2001.5163 PMID: MEDLINE:11846459.
58. Galizia G, Lieto E, De Vita F, Romano C, Orditura M., Castellano P, et al. Circulating levels of interleu-kin-10 and interleukin-6 in gastric and colon cancer patients before and after surgery: relationship with radicality and outcome. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research. 2002; 22(4):473-82. Epub 2002/05/30. doi:10.1089/10799900252952262 PMID: 12034030.